The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Orally Administered Vaccine Market Research Report 2025
Synopsis
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
Global Orally Administered Vaccine market is projected to reach US$ 3746.5 million in 2029, increasing from US$ 2540 million in 2022, with the CAGR of 5.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orally Administered Vaccine market research.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Orally Administered Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Orally Administered Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
Global Orally Administered Vaccine market is projected to reach US$ 3746.5 million in 2029, increasing from US$ 2540 million in 2022, with the CAGR of 5.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Orally Administered Vaccine market research.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Orally Administered Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Orally Administered Vaccine report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Orally Administered Vaccine Market Overview
1.1 Product Overview and Scope of Orally Administered Vaccine
1.2 Orally Administered Vaccine Segment by Type
1.2.1 Global Orally Administered Vaccine Market Value Comparison by Type (2023-2029)
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.2.5 Other
1.3 Orally Administered Vaccine Segment by Application
1.3.1 Global Orally Administered Vaccine Market Value by Application: (2023-2029)
1.3.2 Public
1.3.3 Private
1.4 Global Orally Administered Vaccine Market Size Estimates and Forecasts
1.4.1 Global Orally Administered Vaccine Revenue 2018-2029
1.4.2 Global Orally Administered Vaccine Sales 2018-2029
1.4.3 Global Orally Administered Vaccine Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Orally Administered Vaccine Market Competition by Manufacturers
2.1 Global Orally Administered Vaccine Sales Market Share by Manufacturers (2018-2023)
2.2 Global Orally Administered Vaccine Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Orally Administered Vaccine Average Price by Manufacturers (2018-2023)
2.4 Global Orally Administered Vaccine Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Orally Administered Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Orally Administered Vaccine, Product Type & Application
2.7 Orally Administered Vaccine Market Competitive Situation and Trends
2.7.1 Orally Administered Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Orally Administered Vaccine Players Market Share by Revenue
2.7.3 Global Orally Administered Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Orally Administered Vaccine Retrospective Market Scenario by Region
3.1 Global Orally Administered Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Orally Administered Vaccine Global Orally Administered Vaccine Sales by Region: 2018-2029
3.2.1 Global Orally Administered Vaccine Sales by Region: 2018-2023
3.2.2 Global Orally Administered Vaccine Sales by Region: 2024-2029
3.3 Global Orally Administered Vaccine Global Orally Administered Vaccine Revenue by Region: 2018-2029
3.3.1 Global Orally Administered Vaccine Revenue by Region: 2018-2023
3.3.2 Global Orally Administered Vaccine Revenue by Region: 2024-2029
3.4 North America Orally Administered Vaccine Market Facts & Figures by Country
3.4.1 North America Orally Administered Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Orally Administered Vaccine Sales by Country (2018-2029)
3.4.3 North America Orally Administered Vaccine Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Orally Administered Vaccine Market Facts & Figures by Country
3.5.1 Europe Orally Administered Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Orally Administered Vaccine Sales by Country (2018-2029)
3.5.3 Europe Orally Administered Vaccine Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Orally Administered Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Orally Administered Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Orally Administered Vaccine Sales by Country (2018-2029)
3.6.3 Asia Pacific Orally Administered Vaccine Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Orally Administered Vaccine Market Facts & Figures by Country
3.7.1 Latin America Orally Administered Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Orally Administered Vaccine Sales by Country (2018-2029)
3.7.3 Latin America Orally Administered Vaccine Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Orally Administered Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Orally Administered Vaccine Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Orally Administered Vaccine Sales by Country (2018-2029)
3.8.3 Middle East and Africa Orally Administered Vaccine Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Orally Administered Vaccine Sales by Type (2018-2029)
4.1.1 Global Orally Administered Vaccine Sales by Type (2018-2023)
4.1.2 Global Orally Administered Vaccine Sales by Type (2024-2029)
4.1.3 Global Orally Administered Vaccine Sales Market Share by Type (2018-2029)
4.2 Global Orally Administered Vaccine Revenue by Type (2018-2029)
4.2.1 Global Orally Administered Vaccine Revenue by Type (2018-2023)
4.2.2 Global Orally Administered Vaccine Revenue by Type (2024-2029)
4.2.3 Global Orally Administered Vaccine Revenue Market Share by Type (2018-2029)
4.3 Global Orally Administered Vaccine Price by Type (2018-2029)
5 Segment by Application
5.1 Global Orally Administered Vaccine Sales by Application (2018-2029)
5.1.1 Global Orally Administered Vaccine Sales by Application (2018-2023)
5.1.2 Global Orally Administered Vaccine Sales by Application (2024-2029)
5.1.3 Global Orally Administered Vaccine Sales Market Share by Application (2018-2029)
5.2 Global Orally Administered Vaccine Revenue by Application (2018-2029)
5.2.1 Global Orally Administered Vaccine Revenue by Application (2018-2023)
5.2.2 Global Orally Administered Vaccine Revenue by Application (2024-2029)
5.2.3 Global Orally Administered Vaccine Revenue Market Share by Application (2018-2029)
5.3 Global Orally Administered Vaccine Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Orally Administered Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Orally Administered Vaccine Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Orally Administered Vaccine Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Lanzhou Institute Orally Administered Vaccine Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Corporation Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Serum Institute Orally Administered Vaccine Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Corporation Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Valneva Orally Administered Vaccine Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.6.1 Shanghai United Cell Corporation Information
6.6.2 Shanghai United Cell Description and Business Overview
6.6.3 Shanghai United Cell Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai United Cell Orally Administered Vaccine Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Corporation Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bibcol Orally Administered Vaccine Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Corporation Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.9.4 PaxVax Orally Administered Vaccine Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Corporation Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Vabiotech Orally Administered Vaccine Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Corporation Information
6.11.2 Tiantan Biological Orally Administered Vaccine Description and Business Overview
6.11.3 Tiantan Biological Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Tiantan Biological Orally Administered Vaccine Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Corporation Information
6.12.2 EuBiologics Orally Administered Vaccine Description and Business Overview
6.12.3 EuBiologics Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.12.4 EuBiologics Orally Administered Vaccine Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Corporation Information
6.13.2 Panacea Biotec Ltd Orally Administered Vaccine Description and Business Overview
6.13.3 Panacea Biotec Ltd Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Panacea Biotec Ltd Orally Administered Vaccine Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Corporation Information
6.14.2 Bio-Med Orally Administered Vaccine Description and Business Overview
6.14.3 Bio-Med Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bio-Med Orally Administered Vaccine Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
6.15.2 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Halfkin Bio-Pharmaceuticals Orally Administered Vaccine Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Orally Administered Vaccine Industry Chain Analysis
7.2 Orally Administered Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Orally Administered Vaccine Production Mode & Process
7.4 Orally Administered Vaccine Sales and Marketing
7.4.1 Orally Administered Vaccine Sales Channels
7.4.2 Orally Administered Vaccine Distributors
7.5 Orally Administered Vaccine Customers
8 Orally Administered Vaccine Market Dynamics
8.1 Orally Administered Vaccine Industry Trends
8.2 Orally Administered Vaccine Market Drivers
8.3 Orally Administered Vaccine Market Challenges
8.4 Orally Administered Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
